Structured treatment interruptions in HIV/AIDS therapy

Microbes and Infection

Volumn 4, Issue 2, 2002, Pages 207-214

  Lisziewicz, Julianna ^a   Lori, Franco ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Research Institute for Genetic and Human Therapy   (United States)

Author keywords

AIDS; Immune reconstitution; Immunotherapy; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HYDROXYUREA; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNITY; DIARRHEA; DRUG INDUCED DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; INFECTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; TOXICITY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; RISK; VIRAL LOAD;

EID: 0036189290     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01529-5     Document Type: Review

References (35)

1. Adverse effects of antiretroviral therapy
2. Mitochondrial toxicity and HIV therapy
3. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
4. HIV suppressed long after treatment
5. Control of HIV despite the discontinuation of antiretroviral therapy
6. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion
7. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
8. Structured treatment interruptions to control HIV
9. Immune control of HIV-1 after early treatment of acute infection
10. Control of SIV rebound through structured treatment interruptions during early infection
11. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
12. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
13. H.A.A.R.T. Pre-, HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
14. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection
15. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
16. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
17. SSITT: A prospective trial of strategic treatment interruptions in 128 patients
18. Skewed maturation of memory HIV-specific CD8 T lymphocytes
19. The T cell receptor V beta repertoire in HIV-1 infection and disease
20. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences
21. Alterations of T-cell receptor variable region expression in human immunodeficiency virus disease
22. The dynamics of CD4+ T-cell depletion in HIV disease
23. Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression
24. Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
25. Short-cycle intermittent HAART: A pilot study
26. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
27. Structured treatment interruptions in antiretroviral management of HIV- 1
28. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
29. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
30. Influence of hydroxyurea (HU) associated with HAART and maintained during periods off antiretroviral therapy in STI on the HIV-1-specific immune responses
31. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity
32. Restoration of immunity after HIV infection
33. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: A randomized controlled trial
34. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
35. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells